Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
Top Cited Papers
- 23 May 2020
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 31 (9), 1216-1222
- https://doi.org/10.1016/j.annonc.2020.05.015
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
- AstraZeneca
- Celgene
- AstraZeneca
This publication has 30 references indexed in Scilit:
- Genetic Basis for Clinical Response to CTLA-4 Blockade in MelanomaThe New England Journal of Medicine, 2014
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014Annals of Oncology, 2014
- Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 MutationsPLOS ONE, 2013
- Signatures of mutational processes in human cancerNature, 2013
- Deciphering Signatures of Mutational Processes Operative in Human CancerCell Reports, 2013
- A clinically relevant gene signature in triple negative and basal-like breast cancerBreast Cancer Research, 2011
- Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working GroupJNCI Journal of the National Cancer Institute, 2011
- Reporting Recommendations for Tumor Marker Prognostic StudiesJournal of Clinical Oncology, 2005
- Multiplexed Screening Assay for mRNA Combining Nuclease Protection with Luminescent Array DetectionASSAY and Drug Development Technologies, 2002
- The CONSORT Statement: Revised Recommendations for Improving the Quality of Reports of Parallel-Group Randomized TrialsJAMA, 2001